Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II second-line therapy in metastatic renal cell carcinoma
2011-005939-78Phase 2Terminated
- Sponsor
- Central European Society for Anticancer Drug Research
- Start
- Mar 2012
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in metastatic renal cell carcinoma (mRCC) comparing Bevacizumab + interferon alfa-2a, Everolimus monotherapy and Axitinib monotherapy (3 arms). Started Mar 2012; status: terminated.
02
Drugs
bevacizumabinterferon alfa-2aeverolimusaxitinib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on 2011-005939-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005939-78.